Healthpeak Properties (DOC) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus is a manageable bar at ~$0.395 FFO as Adjusted per share, and the three-segment story is tracking in-line-to-better on two of three legs; the primary swing factor is whether lab occupancy inflected sequentially as guided, which would validate management’s “year-end recovery” thesis and catalyze a re-rating.

Heading into the Q2 2026 print, Healthpeak’s setup is the most balanced it has been in several quarters. Consensus FFO as Adjusted sits at ~$0.395 per share — a step down from Q1’s $0.45 (which was elevated by on-balance-sheet senior housing acquisitions) and consistent with management’s guided run-rate of ~$0.43 ±$0.01 per quarter. The bar is not demanding. On the positive side, peer read-throughs from HR (outpatient medical same-store NOI +5.1% in Q2), VTR (SHOP NOI +16%), and WELL (SHOP NOI +20.5%) all point to sector-wide tailwinds that should benefit DOC’s two strongest segments. The critical variable is the lab segment: management guided for sequential occupancy improvement from 77.7% in Q1 and net absorption by year-end, but ARE’s Q2 2026 results (operating occupancy down to 86.9% from 87.7% in Q1, driven by key lease expirations in South San Francisco) confirm the life science market remains choppy. DOC’s stock has rallied sharply since the Q1 print — up from ~$17 to ~$22 — pricing in meaningful recovery, which raises the bar for a positive surprise. The wildcard is the pace of Janus Living’s $750M capital deployment into senior housing acquisitions: if Janus Living has closed or contracted additional assets at accretive yields, it could pull forward the ~$0.04/share run-rate accretion management flagged for 2027, providing a positive earnings revision catalyst.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on FFO as Adjusted (~$0.395/share), but the bigger swing factor is lab same-store NOI — consensus expects ~−5.7%, and any sequential occupancy improvement above the Q1 77.7% level would be a positive signal. Senior housing is the upside surprise candidate given peer prints running well above DOC’s guided range.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus and actuals data. All consensus figures as of August 3, 2026. FFO as Adjusted per share is the primary valuation KPI for DOC; operating/adjusted figures are prioritized over GAAP EPS. Q1 2026 actual FFO as Adjusted of $0.45 was management-noted as “elevated” due to on-balance-sheet senior housing acquisitions; guided run-rate is ~$0.43 ±$0.01 per quarter.

Table 2 — Beat / Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: FFO as Adjusted per Share — Diluted ($)

KPI 2: Lab Same-Store NOI Growth (%)

Pattern: DOC has beaten FFO as Adjusted consensus in 7 of the last 8 quarters, with the sole miss in Q4 2025 driven by lab occupancy losses flowing through earnings. Lab same-store NOI has been the more volatile KPI — missing in 3 of the last 8 quarters as the market deteriorated, though Q4 2025 showed a positive surprise as the decline was less severe than feared. Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been revised upward since the Q4 2025 earnings call — FFO as Adjusted raised by $0.01/share at the midpoint following the accretive April buyback, and Nareit FFO trimmed by $0.02 due to Janus Living IPO accounting. Tone has shifted meaningfully more confident, particularly on senior housing and lab leasing momentum.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 FFO as Adjusted have drifted lower since the Q1 print (from ~$0.396 to ~$0.395), consistent with management’s guided step-down from the elevated Q1 level. Full-year estimates have also edged down slightly despite the guidance raise, suggesting the market is skeptical of the back-half recovery. The gap between consensus ($1.571) and guidance midpoint ($1.73) is unusually wide and likely reflects the market’s uncertainty about Janus Living accretion timing and lab recovery pace.

Source: Visible Alpha consensus and actuals data. The wide gap between FY 2026 consensus ($1.571) and guidance midpoint ($1.73) reflects market skepticism about the pace of Janus Living capital deployment accretion and lab recovery. Lab SS NOI estimates have actually improved (become less negative) since the Q1 print, suggesting the market is beginning to price in the occupancy inflection management has guided. Senior housing consensus has surged dramatically, consistent with peer prints from WELL (+20.5% SHOP NOI) and VTR (+16% SHOP NOI) in Q2 2026.

5. Stock Performance

Key Takeaway: DOC has significantly outperformed XLRE and the S&P 500 since the Q1 2026 earnings print on May 5, 2026, rallying from ~$17 to ~$22 (+~29%), driven by a combination of multiple expansion (Janus Living IPO re-rating the senior housing segment at ~20x higher multiple) and improving estimate revisions. The stock has priced in a meaningful recovery, raising the bar for a positive surprise at Q2.

Key Events Since Q1 2026 Earnings (May 5, 2026):

• May 5, 2026: Q1 2026 earnings beat; FFO as Adjusted $0.45 vs. $0.391 consensus; FY 2026 FFO as Adjusted guidance raised to $1.71–$1.75; Janus Living IPO confirmed earnings-neutral for 2026, accretive in 2027.
• May 5, 2026: Blackstone JV recapitalization closed at 6.1% cap rate ($170M proceeds); template established for $700M+ additional outpatient medical recaps.
• April 2026 (disclosed May 5): $100M share buyback at $16.81/share (10%+ FFO yield); $306M remaining under $500M program.
• June 15, 2026: DOC announced Q2 2026 earnings date (August 5, 2026) and conference call details.
• Ongoing: Janus Living deploying $750M of IPO proceeds into senior housing acquisitions through year-end; $400M under contract as of Q1 earnings.

Note: A stock price chart (DOC vs. XLRE vs. S&P 500, indexed to 100 at May 5, 2026 earnings date) would be embedded here in the full production version. DOC has rallied approximately +29% since the Q1 print vs. XLRE +~8% and S&P 500 +~6% over the same period, reflecting the Janus Living multiple re-rating and improving lab sentiment. The stock’s outperformance has been driven primarily by multiple expansion rather than estimate revisions (FY consensus moved only +$0.03 since the print), suggesting sentiment and structural re-rating are the dominant drivers.

6. Material News & Developments

Key Takeaway: The Janus Living IPO (March 2026) is the most transformative development since last earnings — it unlocked a ~20-turn multiple arbitrage on the senior housing portfolio and provides Janus Living with the cost of capital to execute accretive acquisitions that will benefit DOC as 81.6% owner. The Blackstone outpatient JV template and $100M buyback are secondary positives.

• March 2026 — Janus Living IPO Completed at High End of Range: Janus Living, Inc. (NYSE: JAN) completed its IPO generating ~$880M of net proceeds in an oversubscribed and upsized offering. Healthpeak owns 81.6% of Janus Living’s $6.9B market cap (~$5.7B value to DOC). The $240M of current-year FFO from the senior housing portfolio is now valued at a multiple ~20 turns higher than Healthpeak’s implied multiple. Implication: Structural re-rating of DOC’s senior housing exposure; Janus Living now has cost of capital for accretive acquisitions that flow through to DOC earnings.
• March 2026 — Blackstone Outpatient Medical JV Recapitalization: Closed on 80% JV interest sale in a 100%-occupied, 6-property outpatient portfolio (418K sq ft) at $212M gross valuation (~6.1% cap rate, ~$508/sq ft). Generated ~$170M proceeds. DOC retains 20% interest and operating member role. Implication: Establishes template for $700M+ additional outpatient recaps at cap rates ~200 bps inside DOC’s implied stock price — significant NAV-accretive capital recycling.
• April 2026 — $100M Share Buyback at $16.81/Share: Repurchased 5.9M shares at 10%+ FFO yield; $306M remaining under $500M program. Implication: Directly drove the $0.01/share guidance raise; signals management conviction that stock is undervalued.
• Q1 2026 — Senior Housing Acquisitions ($714M, 25 Communities): Closed on $714M of senior housing acquisitions across 25 communities (including JV partner buyout for $314M, Orlando for $119M, Atlanta for $240M, Seattle for $41M), all contributed to Janus Living. Implication: Maintains DOC’s senior housing exposure at December 31 levels despite selling 18% in the IPO; positions Janus Living as a scaled acquirer.
• Q1 2026 — Gateway Campus Acquisition (South San Francisco): Completed in early January at “a small fraction of replacement cost.” 62K sq ft of signed leases/LOIs and 113K sq ft of active proposals/tours as of Q1 earnings. Rents at or above underwriting. Implication: Ahead of schedule; upside expected to materialize in 2027–2028 earnings.
• Q1 2026 — New $400M Unsecured Delayed-Draw Term Loan: Closed in March 2026, maturing March 2031 at SOFR +80 bps; undrawn as of May 5, 2026. Implication: Provides dry powder for opportunistic lab acquisitions once $1B recycling target is met.
• Q1 2026 — Alewife Mixed-Use Project (Cambridge, MA): Received preliminary planning board approval for ~5M sq ft mixed-use project (half multifamily, led by Hines). Entitlements expected Q4 2026; potential groundbreaking 2027. Implication: Long-dated optionality on Boston life science recovery; not in near-term earnings.
• H2 2026 Headwind — $650M Senior Notes Refinancing: $650M of 3.5% senior notes to be refinanced in June 2026 at higher current rates. Management flagged this as “an additional headwind in the second half of the year vs. the first half.” Implication: Interest expense headwind of ~$20M for FY 2026 vs. initial guidance; partially explains the gap between Q1 FFO ($0.45) and guided run-rate ($0.43).
• April 2026 — Biotech Equity Issuance Surge: Management noted April 2026 was the most active month for biotech equity issuance since early 2021. Implication: Positive leading indicator for lab tenant demand and leasing pipeline conversion.

7. Insider Transaction Activity

Key Takeaway: Insider activity since the Q1 2026 earnings print is minimal — only one open-market sale was disclosed, by the CDO and Head of Lab, Scott Bohn, in May 2026. The absence of open-market buying is notable given the stock’s sharp rally, but the single sale is small in dollar terms and not a meaningful negative signal.

Source: SEC Form 4 filings database. Search window: May 5, 2026 – August 3, 2026 (post-Q1 earnings). Only open-market transactions (Form 4 codes P/S) included. No open-market purchases were filed in the period. The sole transaction is a small discretionary sale by the Head of Lab — notable given his segment is the primary earnings headwind, but the size ($185K–$220K estimated) is not material relative to total compensation.

8. Peer Commentary & Read-Through

Methodology Note: This section includes ONLY commentary and results from peers’ Q2 2026 reporting period (quarter ended June 30, 2026) or explicit forward outlook statements made after their Q2 2026 earnings releases. All source documents are dated between June 4, 2026 and August 3, 2026 (within the last 60 days as of the preparation date). Commentary about prior quarters (Q1 2026 or earlier) from these peers is excluded. Peers are organized by DOC segment relevance: ARE for Life Science, HR and VTR for Outpatient Medical, and WELL and VTR for Senior Housing.

8A. Life Science Read-Through — Alexandria Real Estate Equities (ARE)

Source: ARE Q2 2026 Earnings Release (dated August 3, 2026). ARE is the preeminent pure-play life science REIT and DOC’s most direct lab segment read-through, sharing the same AAA cluster markets (Greater Boston, San Francisco Bay Area / South San Francisco, San Diego).

ARE Q2 2026 Key Results (Current Quarter)

ARE Q2 2026 Key Takeaway for DOC: ARE’s Q2 2026 results confirm the life science market is recovering but unevenly — leasing volumes are above recent averages, but occupancy continues to decline sequentially as large lease expirations outpace commencements. The pivot to advanced technology tenants (29% of ARE’s Q2 leasing) is a structural shift that DOC can replicate given its flexible building stock. The most important signal for DOC is ARE’s South San Francisco market: ARE flagged expirations at 1450 Owens Street (137K RSF) and two Palo Alto/South SF properties (71K RSF) as the primary Q2 occupancy drag — the same submarket where DOC holds 210 acres and the Gateway campus. This confirms active demand in South SF but also validates that near-term occupancy pressure is real. ARE’s maintained FFO guidance midpoint (no cut) is a mild positive read-through for sector stability.

8B. Outpatient Medical Read-Through — Healthcare Realty Trust (HR)

Source: HR Q2 2026 Earnings Release and Earnings Call Transcript (dated July 30–31, 2026). HR is the largest pure-play outpatient medical REIT and DOC’s most direct competitor in this segment.

HR Q2 2026 Key Results (Current Quarter)

VTR Q2 2026 Key Takeaway for DOC: VTR’s Q2 2026 results are a strong positive read-through for both of DOC’s non-lab segments. SHOP NOI growth of +16% (US +18%) is consistent with DOC’s Q2 2026 senior housing consensus of ~17%, suggesting DOC is tracking in-line with sector leaders. The 55% incremental margin flow-through and accelerating pricing power at 90%+ occupancy communities illustrate the operating leverage DOC’s CCRCs can capture. VTR’s OMAR segment (+5% same-store NOI, +50 bps occupancy, 88% retention) corroborates HR’s outpatient medical read-through and confirms DOC’s 2%–3% guidance is conservative. VTR’s guidance raise (driven by senior housing investment accretion) validates Janus Living’s acquisition strategy.

8D. Senior Housing Read-Through — Welltower (WELL)

Source: WELL Q2 2026 Earnings Call Transcript (dated July 28, 2026). WELL is the dominant senior housing REIT benchmark and the most important read-through for DOC’s CCRC/Janus Living segment.

WELL Q2 2026 Key Results (Current Quarter)

WELL Q2 2026 Key Takeaway for DOC: WELL’s Q2 2026 results are the most bullish read-through for DOC’s senior housing segment. The 15th consecutive quarter of 20%+ SHOP NOI growth, 65% flow-through margins, and record-low expense growth confirm that the senior housing cycle is in full acceleration. WELL’s observation that communities crossing 90% and 95% occupancy thresholds create “exponential pricing power” is directly relevant to DOC’s CCRCs, which are approaching those thresholds. The supply constraint narrative (construction economics “prohibitive,” WELL abandoning land parcels) is the most durable structural tailwind and supports DOC’s multi-year senior housing growth thesis. WELL’s $0.12 guidance raise (the largest among peers) signals that the sector is outperforming even optimistic expectations.

8E. Consolidated Peer Read-Through Summary

Overall Peer Read-Through Verdict: Two of DOC’s three segments have strong positive read-throughs from Q2 2026 peer results. Outpatient medical (HR +5.1%, VTR OMAR +5%) is running well above DOC’s 2%–3% guidance, and senior housing (WELL +20.5%, VTR +16%) is tracking at or above DOC’s consensus of ~17%. The life science read-through (ARE) is mixed — leasing volumes are recovering but occupancy is still declining sequentially, consistent with DOC’s own guided trajectory. The net read-through is modestly positive for the Q2 2026 print, with the primary upside risk in outpatient medical and senior housing, and the primary uncertainty remaining in lab occupancy.

Time-Screen Methodology: All peer commentary in this section is sourced exclusively from Q2 2026 earnings releases and call transcripts dated July 28 – August 3, 2026 (ARE Q2 2026 Earnings Release: August 3, 2026; HR Q2 2026 Earnings Release and Call: July 30–31, 2026; VTR Q2 2026 Earnings Release and Call: July 29–30, 2026; WELL Q2 2026 Earnings Call: July 28, 2026). No commentary from prior quarters (Q1 2026 or earlier) has been included. Forward outlook statements are included only where peers explicitly addressed Q3 2026 or full-year 2026 expectations in their Q2 2026 earnings communications.